Resolving inflammatory organ disease through macrophage cell therapy

Inflammatory organ disease affects millions of patients worldwide. We aim to treat these patients, for example by helping patients with liver cirrhosis avoiding the need for a transplantation.

The Science +

Harnessing the healing power of the macrophage

Resolution Therapeutics is developing macrophage cell therapies to treat diseases characterised by life-threatening inflammatory organ damage. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, manufacture and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes.

Latest News


Resolution Appoints Liver Disease Expert, Dr Clifford A. Brass, as Chief Medical Officer

London, 2 May 2023 – Resolution Therapeutics announces the appointment of Dr. Clifford A. Brass, as Chief Medical Officer.


Resolution Expands its CMC Capabilities with Key Hires

London, 30 March 2023 - Resolution Therapeutics announces the appointment of key senior CMC hires in regulatory, quality, process development, analytical development and project management.


Resolution Therapeutics Announces the Appointment of Lisa Bright as Chair of its Board of Directors

London, 9 November 2022 - Resolution announced today the appointment of Lisa Bright as Chairman of its Board of Directors


Resolution Therapeutics and CCRM sign collaboration agreement to develop and scale up manufacturing for iPSC-derived macrophage cell therapies

London, UK and Toronto, Canada, 7 November, 2022 – Resolution Therapeutics and CCRM announce the signing of a collaboration in iPSC-derived macrophage cell therapies.


Resolution Therapeutics Appoints Bill Symonds to its Board of Directors

London, 20 April 2021 – Resolution Therapeutics announces the appointment of Bill Symonds as a Non-Executive Director of the Company.


Chairman's Statement

Resolution is at the forefront of a new kind of cell therapy. We’re treating inflammatory organ disease with macrophages, the cells that the body uses to resolve injury and heal wounds. Our work builds on a huge body of science understanding the role of macrophages as orchestrators of the wound healing process; coupled with our world-leading founders, a top-quality scientific staff and proprietary insight into macrophage biology and manufacturing, we are poised to improve the lives of countless patients worldwide.

Edward Hodgkin Chairman & CEO